Literature DB >> 7805312

Well differentiated astrocytoma occurring nine years after radiation therapy for medulloblastoma.

A K Osumi1, R E Mclendon, R D Tien, H S Friedman, M Graham, B Hockenberger, E C Halperin, W J Oakes.   

Abstract

Conventional treatment for medulloblastoma includes surgical resection followed by craniospinal irradiation, with the potential risk of subsequent radiotherapy-induced secondary neoplasms. We report a 23-year-old woman previously irradiated nine years earlier for a cerebellar medulloblastoma who developed a new enhancing lesion in the primary radiation field four weeks following completion of high dose chemotherapy with bone marrow transplantation for recurrent disease. Resection of this lesion revealed a low grade glioma with no evidence of recurrent medulloblastoma.

Entities:  

Mesh:

Year:  1994        PMID: 7805312

Source DB:  PubMed          Journal:  Clin Neuropathol        ISSN: 0722-5091            Impact factor:   1.368


  4 in total

Review 1.  Radiation-induced gliomas: a comprehensive review and meta-analysis.

Authors:  Ryuya Yamanaka; Azusa Hayano; Tomohiko Kanayama
Journal:  Neurosurg Rev       Date:  2016-10-05       Impact factor: 3.042

Review 2.  Metachronous secondary atypical meningioma and anaplastic astrocytoma after postoperative craniospinal irradiation for medulloblastoma.

Authors:  Andrew J Hope; David B Mansur; Pang-Hsien Tu; Joseph R Simpson
Journal:  Childs Nerv Syst       Date:  2006-03-29       Impact factor: 1.475

3.  Gliosarcoma occurring 8 years after treatment for a medulloblastoma.

Authors:  Rohit Malde; Rakesh Jalali; Dattatraya Muzumdar; Tanuja Shet; Purna Kurkure
Journal:  Childs Nerv Syst       Date:  2003-12-24       Impact factor: 1.475

Review 4.  Radiation-induced brain tumours after central nervous system irradiation in childhood: a review.

Authors:  Benedetta Ludovica Pettorini; Young-Soo Park; Massimo Caldarelli; Luca Massimi; Gianpiero Tamburrini; Concezio Di Rocco
Journal:  Childs Nerv Syst       Date:  2008-04-08       Impact factor: 1.475

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.